Anemia Management News

PHILADELPHIA — Patients with chronic kidney disease on dialysis who received daprodustat had fewer vascular access thrombosis events compared with patients who had erythropoiesis-stimulating agents, according to data presented here.

The FDA has set a user fee goal date of March 27, 2024, for review of the oral hypoxia-inducible factor prolyl hydroxylase inhibitor vadadustat for the treatment of anemia in adults on dialysis.

Healio spoke with Jay B. Wish, MD, about managing anemia in patients on dialysis.

Healio spoke with Jay B. Wish, MD, about unmet needs in the management of anemia.

Healio spoke with Jay B. Wish, MD, about managing anemia in patients on dialysis.

Healio spoke with Jay B. Wish, MD, about treatment approaches in patients with CKD and anemia.

Healio spoke with Jay B. Wish, MD, about managing challenging cases of anemia.

Healio spoke with Jay B. Wish, MD, about new developments in anemia care.

Akebia Therapeutics Inc. has resubmitted its new drug application to the FDA for vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in adults on dialysis.

While clinical trials have shown hypoxia-inducible factor prolyl hydroxylase inhibitors to be non-inferior to other anemia drugs, questions remain about IV or oral iron supplementation and inflammation, according to a new report.